Letybo

Botulinum Toxin Type A, the active ingredient in Letybo, is a neuromuscular blocking agent presented as a sterile injectable for intramuscular use. It is employed to induce temporary muscle paralysis in therapeutic settings such as movement‑disorder and spasticity management.

GNH USA supplies Letybo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Botulinum Toxin Type A is used to treat disorders involving abnormal muscle overactivity.

- Cervical dystonia: reduces painful neck muscle contractions. - Blepharospasm: relieves involuntary eyelid closure. - Chronic migraine: decreases frequency of migraine attacks. - Upper‑limb spasticity: improves range of motion in post‑stroke patients. - Severe axillary hyperhidrosis: diminishes excessive sweating.

Botulinum Toxin Type A may cause a range of adverse reactions, most of which are related to the injection site or systemic spread of the toxin.

Common Side Effects: - Injection site pain or bruising. - Localized muscle weakness. - Headache. - Dry mouth. - Flu‑like symptoms. - Transient eyelid drooping (ptosis) when used near the eyes.

Serious or Rare Side Effects: - Dysphagia or difficulty swallowing. - Respiratory compromise due to spread to respiratory muscles. - Generalized muscle weakness. - Allergic reactions such as rash, itching, or anaphylaxis. - Vision changes including double vision. - Systemic botulism‑like syndrome.

Prior to administration, clinicians should evaluate patient history and potential risk factors.

- Contraindication: Do not use in patients with known hypersensitivity to botulinum toxin preparations. - Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus. - Breastfeeding: Caution advised; limited data on excretion in breast milk. - Neuromuscular disorders: Avoid or use with extreme caution in patients with myasthenia gravis or Lambert‑Eaton syndrome. - Dosing: Adjust dose in pediatric patients and the elderly based on clinical response. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Botulinum Toxin Type A can interact with other agents that affect neuromuscular transmission.

Major Interactions (Avoid): - Aminoglycoside antibiotics (e.g., gentamicin, streptomycin): may potentiate neuromuscular blockade. - Curare‑type muscle relaxants: increase risk of profound paralysis. - Magnesium sulfate: can enhance the blocking effect.

Moderate Interactions (Monitor Closely): - Anticholinesterase drugs (e.g., pyridostigmine): may reduce the efficacy of the toxin. - Other botulinum toxin products: cumulative dosing may increase systemic exposure. - General anesthetics that depress neuromuscular function: monitor respiratory status.